The below reason why Boehringer results are so big for us, transformative for the company and a takeover target from Boehringer plus why major shareholders are still buying at these prices in my opinion:
“A combination of TRPC3 and TRPC6 inhibitors may be more effective in treating kidney fibrosis than using either inhibitor alone. Studies have shown that inhibiting both TRPC3 and TRPC6 channels can significantly reduce renal fibrosis, with some studies suggesting this combination is more effective than inhibiting either channel individually”
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $62.22M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.5¢ | 28.0¢ | $128.2K | 450.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 61694 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |